158 related articles for article (PubMed ID: 37300512)
1. Safety of Biologic and Small Molecule Therapy for Inflammatory Bowel Disease Among Solid Organ Transplant Recipients: Systematic Review and Meta-Analysis.
Taneja V; Anand RS; El-Dallal M; Dong J; Desai N; Taneja I; Feuerstein JD
Inflamm Bowel Dis; 2024 Apr; 30(4):585-593. PubMed ID: 37300512
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of biologic therapy in microscopic colitis: systematic review and meta-analysis.
Taneja V; El-Dallal M; Anand RS; Haq Z; Mishkin B; Feuerstein JD
Eur J Gastroenterol Hepatol; 2022 Oct; 34(10):1000-1006. PubMed ID: 36052677
[TBL] [Abstract][Full Text] [Related]
3. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
Gisbert JP; Chaparro M
J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
[TBL] [Abstract][Full Text] [Related]
4. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
[TBL] [Abstract][Full Text] [Related]
6. Comparative Analysis of 3-Year Persistence With Vedolizumab Compared With Antibodies Against Tumor Necrosis Factor-Alpha in Patients With Inflammatory Bowel Disease in Germany: Retrospective Analysis of a Large Prescription Database.
Helwig U; Kostev K; Schmidt C
J Clin Gastroenterol; 2021 Jan; 55(1):e1-e7. PubMed ID: 32011403
[TBL] [Abstract][Full Text] [Related]
7. Selection strategy of second-line biologic therapies in adult patients with ulcerative colitis following prior biologic treatment failure: Systematic review and meta-analysis.
Zhang H; Mu C; Gu Y; Meng F; Qin X; Cao H
Pharmacol Res; 2024 Apr; 202():107108. PubMed ID: 38403257
[TBL] [Abstract][Full Text] [Related]
8. Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
Bots SJ; Parker CE; Brandse JF; Löwenberg M; Feagan BG; Sandborn WJ; Jairath V; D'Haens G; Vande Casteele N
BioDrugs; 2021 Nov; 35(6):715-733. PubMed ID: 34797516
[TBL] [Abstract][Full Text] [Related]
9. Comparative Efficacy of Biologic Therapies for Inducing Response and Remission in Fistulizing Crohn's Disease: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Shehab M; Alrashed F; Heron V; Restellini S; Bessissow T
Inflamm Bowel Dis; 2023 Mar; 29(3):367-375. PubMed ID: 35604382
[TBL] [Abstract][Full Text] [Related]
10. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
[TBL] [Abstract][Full Text] [Related]
11. Safety, Efficacy and Persistence of Advanced Therapies in Inflammatory Bowel Disease: Results from ORIGINS. A Retrospective Observational Study.
Mateescu RB; Gheorghe C; Trifan AV; Saftoiu A; Seicean A; Diculescu MM; Banciu C; Gheorghe LS; Busuioc B; Goldis A; Dobru D; Fratila O; Eugen D; Bataga S; Constantinescu G; Gheonea D; Tantau A; Jinga M; Brisc C; Cijevschi Prelipcean C; Chira R; Fierbințeanu-Braticevici C; Dumitrascu D; State M; Voiosu T; Negreanu L
J Gastrointestin Liver Dis; 2023 Dec; 32(4):444-451. PubMed ID: 38147607
[TBL] [Abstract][Full Text] [Related]
12. Safety of biologic treatments in solid organ transplant recipients: A systematic review.
Meyer F; Weil-Verhoeven D; Prati C; Wendling D; Verhoeven F
Semin Arthritis Rheum; 2021 Dec; 51(6):1263-1273. PubMed ID: 34507811
[TBL] [Abstract][Full Text] [Related]
13. No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-analysis.
Yzet C; Diouf M; Singh S; Brazier F; Turpin J; Nguyen-Khac E; Meynier J; Fumery M
Clin Gastroenterol Hepatol; 2021 Apr; 19(4):668-679.e8. PubMed ID: 32629124
[TBL] [Abstract][Full Text] [Related]
14. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
15. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
Singh S; Facciorusso A; Dulai PS; Jairath V; Sandborn WJ
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):69-81.e3. PubMed ID: 30876964
[TBL] [Abstract][Full Text] [Related]
16. The impact of biological interventions for ulcerative colitis on health-related quality of life.
LeBlanc K; Mosli MH; Parker CE; MacDonald JK
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD008655. PubMed ID: 26393522
[TBL] [Abstract][Full Text] [Related]
17. Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
Solitano V; Facciorusso A; Jess T; Ma C; Hassan C; Repici A; Jairath V; Armuzzi A; Singh S
Clin Gastroenterol Hepatol; 2023 Apr; 21(4):907-921.e2. PubMed ID: 35944832
[TBL] [Abstract][Full Text] [Related]
18. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
Ahmed W; Galati J; Kumar A; Christos PJ; Longman R; Lukin DJ; Scherl E; Battat R
Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e361-e379. PubMed ID: 33798711
[TBL] [Abstract][Full Text] [Related]
19. Safety of Combination Biologic and Antirejection Therapy Post-Liver Transplantation in Patients With Inflammatory Bowel Disease.
Al Draiweesh S; Ma C; Alkhattabi M; McDonald C; Nguyen TM; Beaton M; Chande N; Colquhoun P; Feagan BG; Gregor JC; Khanna R; Marotta P; Ponich T; Quan D; Qumosani K; Sandhu A; Sey M; Skaro A; Teriaky A; Wilson A; Yan B; Brahmania M; Jairath V
Inflamm Bowel Dis; 2020 May; 26(6):949-959. PubMed ID: 31665288
[TBL] [Abstract][Full Text] [Related]
20. Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis.
Esse S; Mason KJ; Green AC; Warren RB
JAMA Dermatol; 2020 Jul; 156(7):787-794. PubMed ID: 32432649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
